|
1
|
Mariño-Enríquez A, Wang WL, Roy A,
Lopez-Terrada D, Lazar AJ, Fletcher CD, Coffin CM and Hornick JL:
Epithelioid inflammatory myofibroblastic sarcoma: An aggressive
intra-abdominal variant of inflammatory myofibroblastic tumor with
nuclear membrane or perinuclear ALK. Am J Surg Pathol. 35:135–144.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Yu L, Liu J, Lao IW, Luo Z and Wang J:
Epithelioid inflammatory myofibroblastic sarcoma: A
clinicopathological, immunohistochemical and molecular cytogenetic
analysis of five additional cases and review of the literature.
Diagn Pathol. 11:672016. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Liu Q, Kan Y, Zhao Y, He H and Kong L:
Epithelioid inflammatory myofibroblastic sarcoma treated with ALK
inhibitor: A case report and review of literature. Int J Clin Exp
Pathol. 8:15328–15332. 2015.PubMed/NCBI
|
|
4
|
Kruczynski A, Delsol G, Laurent C,
Brousset P and Lamant L: Anaplastic lymphoma kinase as a
therapeutic target. Expert Opin Ther Targets. 16:1127–1138. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Kimbara S, Takeda K, Fukushima H, Inoue T,
Okada H, Shibata Y, Katsushima U, Tsuya A, Tokunaga S, Daga H, et
al: A case report of epithelioid inflammatory myofibroblastic
sarcoma with RANBP2-ALK fusion gene treated with the ALK inhibitor,
crizotinib. Jpn J Clin Oncol. 44:868–871. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Heigener DF and Reck M: Crizotinib. Recent
Results Cancer Res. 211:57–65. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Voena C and Chiarle R: The battle against
ALK resistance: Successes and setbacks. Expert Opin Investig Drugs.
21:1751–1754. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Su D, Zhang D, Chen K, Lu J, Wu J, Cao X,
Ying L, Jin Q, Ye Y, Xie Z, et al: High performance of targeted
next generation sequencing on variance detection in clinical tumor
specimens in comparison with current conventional methods. J Exp
Clin Cancer Res. 36:1212017. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Fang H, Langstraat CL, Visscher DW, Folpe
AL and Schoolmeester JK: Epithelioid inflammatory myofibroblastic
sarcoma of the ovary with RANB2-ALK fusion: Report of a case. Int J
Gynecol Pathol. 37:468–472. 2018.PubMed/NCBI
|
|
10
|
Lee JC, Li CF, Huang HY, Zhu MJ,
Mariño-Enríquez A, Lee CT, Ou WB, Hornick JL and Fletcher JA: ALK
oncoproteins in atypical inflammatory myofibroblastic tumours:
Novel RRBP1-ALK fusions in epithelioid inflammatory myofibroblastic
sarcoma. J Pathol. 241:316–323. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Fang N, Yang QJ, Deng YT, Feng X, Xia HS,
Zhang YG, Wang MW, Wu D, Zhou H and Guo F: Epithelioid inflammatory
myofibroblastic sarcoma of small bowel mesentery: Report of a case.
Zhonghua Bing Li Xue Za Zhi. 46:201–202. 2017.(In Chinese).
PubMed/NCBI
|
|
12
|
Mansfield AS, Murphy SJ, Harris FR,
Robinson SI, Marks RS, Johnson SH, Smadbeck JB, Halling GC, Yi ES,
Wigle D, et al: Chromoplectic TPM3-ALK rearrangement in a patient
with inflammatory myofibroblastic tumor who responded to ceritinib
after progression on crizotinib. Ann Oncol. 27:2111–2117. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Michels SYF, Scheel AH, Wündisch T,
Heuckmann JM, Menon R, Puesken M, Kobe C, Pasternack H, Heydt C,
Scheffler M, et al: ALKG1269A mutation as a potential mechanism of
acquired resistance to crizotinib in an ALK-rearranged inflammatory
myofibroblastic tumor. NPJ Precis Oncol. 1:42017. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Sasaki T, Okuda K, Zheng W, Butrynski J,
Capelletti M, Wang L, Gray NS, Wilner K, Christensen JG, Demetri G,
et al: The neuroblastoma-associated F1174L ALK mutation causes
resistance to an ALK kinase inhibitor in ALK-translocated cancers.
Cancer Res. 70:10038–10043. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Nishio M, Murakami H, Horiike A, Takahashi
T, Hirai F, Suenaga N, Tajima T, Tokushige K, Ishii M, Boral A, et
al: Phase I study of ceritinib (ldk378) in Japanese patients with
Advanced, Anaplastic lymphoma kinase-rearranged non-small-cell lung
cancer or other tumors. J Thorac Oncol. 10:1058–1066. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Katayama R, Lovly CM and Shaw AT:
Therapeutic targeting of anaplastic lymphoma kinase in lung cancer:
A paradigm for precision cancer medicine. Clin Cancer Res.
21:2227–2235. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Huang WS, Liu S, Zou D, Thomas M, Wang Y,
Zhou T, Romero J, Kohlmann A, Li F, Qi J, et al: Discovery of
brigatinib (AP26113), a phosphine oxide-containing, potent, orally
active inhibitor of anaplastic lymphoma kinase. J Med Chem.
59:4948–4964. 2016. View Article : Google Scholar : PubMed/NCBI
|
